New EU Pharmaceutical Legislation (Pharma Package)
Author: Giulia Bruno, Head of Regulatory Affairs, Arithmos
Executive Summary
The EU Pharmaceutical Package is not just a regulatory update, it is a structural shift in how pharmaceutical value will be earned in Europe. Incentives and exclusivity will increasingly depend on demonstrated public health impact, timely patient access, and resilience of supply.
Although the new rules are expected to apply from 2028, the strategic implications start now: companies that wait risk losing flexibility, incentives, and competitive positioning.
Regulation is no longer only a compliance requirement. It has become a key driver of strategy, competitiveness and long-term value creation. Companies are now expected to demonstrate not only scientific innovation, but also tangible contributions to public health priorities, access to medicines, and security of supply.
In this context, Regulatory Affairs (RA) emerges as a critical strategic partner for pharmaceutical companies. A proactive and integrated RA approach can support complex decision-making, reduce regulatory risk and enable companies to turn regulatory change into a competitive advantage. This white paper highlights the key elements of the reform and outlines how Regulatory Affairs can actively support stakeholders in navigating and leveraging the new framework.
Download '.pdf' Format of the whitepaper.
